Table 2.
Comparison of TCID50, PFU and MOI amounts in clinical and cloned EV71
| Virus | 100 TCID50a (per mL) | PFUb (per mL) | MOIc in the plaquing assay | MOIc in the TCID50 assay | |||
|---|---|---|---|---|---|---|---|
| Actual | Predicted | Actual | Predicted | Actual | Predicted | ||
| Cloned EV71e | 4.5 × 101 (5.5 × 102)d | 33,180 ± 4,728 | 315,000 (3,850,000)d | 0.09 ± 0.01 | 0.9 (10.7)d | 0.04 ± 0.01 | 0.4 (5.1)d |
| Clinically isolated EV71e | 8 × 101 (4.8 × 102)d | 30,856 ± 13,546 | 560,000 (3,360,000)d | 0.09 ± 0.03 | 1.5 (9.3)d | 0.04 ± 0.02 | 0.7 (4.4)d |
aThe MTT-based virus titration was used to measure 100 TCID50 on samples of cloned EV71 and clinically isolated EV71 that were directly used in the plaquing assays mentioned in this table
bThe actual values of PFU were generated from the plaquing assays (mean ± SD) based on the 100 TCID50 virus samples, while the predicted PFUs were calculated using the conversion factor 0.7
cThe actual and the predicted values of MOI were calculated based on the actual and the predicted values of PFUs, respectively
dIndicated in the parentheses are values generated based on the modified traditional TCID50
eThere was no statistically significant difference in PFU or MOI between cloned EV71 and clinical EV71